Scientific Board

Geoffrey Burgess, MD

Dr. Burgess is currently Chief Medical Officer at Glutalor Medical. Dr. Burgess just retired after 40 years practice as a family medicine specialist with focus on diabetes in west Philadelphia area. Dr. Burgess graduated from Pennsylvania State University College of Medicine in 1975. Dr. Burgess founded Gateway Medical Associates in 1986 and worked as Medical Director at Tandigm Health from 2014 to 2017.

David A Simmons, MD

David A. Simmons, MD, a diabetologist for more than 40 years, is Principal at Diabetes Management Consultants, LCC, Villanova, Pennsylvania. He received his medical degree at the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.

Dr Simmons recently retired after serving as Vice President and Chief Medical Officer at Ascensia Diabetes Care where he provided senior leadership during the transition of this company from a division of Bayer Diabetes Care into a stand-alone medical solutions company in Parsippany, New Jersey. Previously, he was Vice President and Chief Medical Officer of Bayer Health Care, Diabetes Care, from 2007 to 2015. Before joining Bayer, Dr Simmons directed clinical research teams whose work was instrumental in the development and launch of Exubera as well as other components of Pfizer’s cardiometabolic portfolio. He was the recipient of the Outstanding Achievement in Diabetes Service award from the Pennsylvania affiliate of the American Diabetes Association in 1995.

Gerard Marriott, PhD, Professor, Bioengineering, UC Berkeley

Prof. Marriott received a BSc (Hons) in Biochemistry from Birmingham University in the UK in 1980, and a Ph.D. from the University of Illinois in 1987. He was awarded prestigious fellowships from the Alexander von Humboldt Stiftung. After serving as a C3-professor at the Max Planck Institute for Biochemistry in Martinsried, he was recruited by the University of Wisconsin-Madison in 1999 to lead a new biophotonics initiative. In 2009 he moved to the Bioengineering department at UC-Berkeley where he conducts research on the design and development of novel biosensors and technology platforms for multi-scale in vitro and in vivo imaging and tumor-targeted drug delivery.  Prof. Marriott is also a co-Director of the Center for Precision Medicine and Healthcare at the Tsinghua-Berkeley Shenzhen Institute, where he is developing innovative biosensors for wearable devices to monitor glucose, cancer biomarkers and circulating tumor cells.